Advances in Biology, Diagnosis and Treatment of DLBCL

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Jul 17

PMID 39017945

Authors

Yuanfei Shi

Yi Xu

Huafei Shen

Jie Jin

Hongyan Tong

Wanzhuo Xie

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphoma (DLBCL), with approximately 150,000 new cases worldwide each year, represent nearly 30% of all cases of non-Hodgkin lymphoma (NHL) and are phenotypically and genetically heterogeneous. A gene-expression profile (GEP) has identified at least three major subtypes of DLBCL, each of which has distinct clinical, biological, and genetic features: activated B-cell (ABC)-like DLBCL, germinal-center B-cell (GCB)-like DLBCL, and unclassified. Different origins are associated with different responses to chemotherapy and targeted agents. Despite DLBCL being a highly heterogeneous disease, more than 60% of patients with DLBCL can be cured after using rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to inhibit the growth of cancer cells while targeting the CD20 receptor. In recent decades, the improvement of diagnostic levels has led to a refinement classification of DLBCL and the development of new therapeutic approaches. The objective of this review was to summarize the latest studies examining genetic lesions and therapies for DLBCL.

Citing Articles

Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma.

Yijia Z, Li X, Ma L, Wang S, Du H, Wu Y Cancer Immunol Immunother. 2025; 74(4):131.

PMID: 40029433 PMC: 11876501. DOI: 10.1007/s00262-025-03972-x.

References

Testoni M, Zucca E, Young K, Bertoni F . Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol. 2015; 26(6):1069-1080. PMC: 4542576. DOI: 10.1093/annonc/mdv019. View

Roschewski M, Staudt L, Wilson W . Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2013; 11(1):12-23. PMC: 7709161. DOI: 10.1038/nrclinonc.2013.197. View

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

Martinez-Climent J, Alizadeh A, Segraves R, Blesa D, Rubio-Moscardo F, Albertson D . Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood. 2002; 101(8):3109-17. DOI: 10.1182/blood-2002-07-2119. View

Kridel R, Sehn L, Gascoyne R . Can histologic transformation of follicular lymphoma be predicted and prevented?. Blood. 2017; 130(3):258-266. DOI: 10.1182/blood-2017-03-691345. View

Bouska A, McKeithan T, Deffenbacher K, Lachel C, Wright G, Iqbal J . Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood. 2013; 123(11):1681-90. PMC: 3954050. DOI: 10.1182/blood-2013-05-500595. View

Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes A . Genetics of follicular lymphoma transformation. Cell Rep. 2014; 6(1):130-40. PMC: 4100800. DOI: 10.1016/j.celrep.2013.12.027. View

Rossi D, Gaidano G . Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009; 27(1):1-10. DOI: 10.1002/hon.880. View

Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita P, Strefford J . Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013; 122(15):2673-82. DOI: 10.1182/blood-2013-03-489518. View

10.

Tiirikainen M, Mullaney B, Holly E, Pallavicini M, Jensen R . DNA copy number alterations in HIV-positive and HIV-negative patients with diffuse large-cell lymphomas. J Acquir Immune Defic Syndr. 2001; 27(3):272-6. DOI: 10.1097/00126334-200107010-00009. View

11.

Gucalp A, Noy A . Spectrum of HIV lymphoma 2009. Curr Opin Hematol. 2010; 17(4):362-7. DOI: 10.1097/MOH.0b013e328338f6b6. View

12.

Carbone A, Gloghini A, Capello D, Gaidano G . Genetic pathways and histogenetic models of AIDS-related lymphomas. Eur J Cancer. 2001; 37(10):1270-5. DOI: 10.1016/s0959-8049(01)00119-8. View

13.

Frontzek F, Lenz G . Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications. Expert Rev Clin Pharmacol. 2019; 12(11):1059-1067. DOI: 10.1080/17512433.2019.1683447. View

14.

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

15.

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

16.

Wright G, Huang D, Phelan J, Coulibaly Z, Roulland S, Young R . A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020; 37(4):551-568.e14. PMC: 8459709. DOI: 10.1016/j.ccell.2020.03.015. View

17.

Barraclough A, Alzahrani M, Ettrup M, Bishton M, van Vliet C, Farinha P . COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Adv. 2019; 3(13):2013-2021. PMC: 6616265. DOI: 10.1182/bloodadvances.2019000251. View

18.

Kumar A, Lunning M, Zhang Z, Migliacci J, Moskowitz C, Zelenetz A . Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2015; 171(5):776-83. PMC: 4715539. DOI: 10.1111/bjh.13766. View

19.

Cunningham D, Hawkes E, Jack A, Qian W, Smith P, Mouncey P . Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013; 381(9880):1817-26. DOI: 10.1016/S0140-6736(13)60313-X. View

20.

Scott D, Mottok A, Ennishi D, Wright G, Farinha P, Ben-Neriah S . Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol. 2015; 33(26):2848-56. PMC: 4554747. DOI: 10.1200/JCO.2014.60.2383. View